Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.73 |
| ▸ | MAOA | P21397 | 1/20 | 0.73 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560021 | 0.88 | MAOB (0.70) | MAOBMAOAFFAR1MAPTALDH1A1 | |
| SCHEMBL6599866 | 0.88 | MAOB (0.68) | MAOBMAOAFFAR1MAPTALDH1A1 | |
| SCHEMBL28299036 | 0.87 | MAOB (0.67) | MAOBMAOAFFAR1MAPTALDH1A1 | |
| SCHEMBL12010999 | 0.87 | MAOB (0.67) | MAOBMAOAFFAR1MAPTALDH1A1 | |
| SCHEMBL27863133 | 0.87 | MAOB (0.67) | MAOBMAOAFFAR1MAPTALDH1A1 | |
| SCHEMBL13192710 | 0.87 | MAOB (0.70) | MAOBMAOAFFAR1ALDH1A1 | |
| SCHEMBL8991408 | 0.86 | MAOB (0.79) | MAOBMAOAFFAR1MAPTALDH1A1 | |
| SCHEMBL12533265 | 0.85 | MAOB (0.66) | MAOBMAOAFFAR1MAPTALDH1A1 | |
| Hydroquinone SCHEMBL29014236 | 0.85 | MAOB (0.61) | MAOBMAOAMAPTALDH1A1MEN1 | |
| SCHEMBL3499926 | 0.85 | MAOB (0.69) | MAOBMAOAFFAR1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189059-B1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2023-02-22 | — | — | EP | disclosed |
| US-10183952-B2 | Thienopyrroles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2019-01-22 | — | — | US | disclosed |
| US-20170260197-A1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2017-09-14 | — | — | US | disclosed |
| EP-3189059-A2 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | Istituto Europeo di Oncologia S.r.l. (IT) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034946-A2 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2016-03-10 | — | — | WO | disclosed |
| EP-2993175-A1 | Thienopyrroles as histone demethylase inhibitors | IEO - Istituto Europeo di Oncologia Srl (IT) | 2016-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183952-B2 | Thienopyrroles as histone demethylase inhibitors | KDM1A, KDM1B, KDM3A | MAOB 1546/4885MAOA 2008/4885FFAR1 2035/4885 |
| US-20170260197-A1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | KDM1A, KDM1B, KDM3A | MAOB 1546/4885MAOA 2008/4885FFAR1 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.